Oxford BioMedica has presented further 'encouraging' data from six Phase II trials of TroVax, at the 14th International Cancer Immunotherapy Meeting, 4-6 October 2006 in New York City
The presentation comprised an analysis of immune responses induced against the 5T4 tumour antigen by TroVax in 63 patients.
In addition to immunological data from two completed Phase II trials of TroVax with standard chemotherapy in colorectal cancer, the analysis included new data from four ongoing Phase II trials of TroVax alongside standard therapies in renal cancer and prostate cancer.
The results showed that 84% of patients had 5T4-specific antibody responses after three injections of TroVax.
5T4-specific cellular responses were evident in 87% of patients in the two trials in colorectal cancer, and preliminary analyses also show cellular responses in the renal cancer and prostate cancer trials.
These data demonstrate that TroVax can be administered both safely and also without loss of immunological efficacy in these three types of cancer alongside numerous co-medications.
Mike McDonald, Oxford BioMedica's chief medical officer, commented on the immunological analysis: "Stimulating a significant and sustainable anti-cancer immune response has been a challenge for the field of cancer immunotherapy.
"TroVax has been shown to induce consistently strong immune responses in multiple cancer settings even when administered alongside other therapies.
"These data confirm the breadth of potential application for TroVax and increase our confidence in its therapeutic effect as we start Phase III development."
